Health Condition 1: J452- Mild intermittent asthma
Conditions
Interventions
Intervention1: Beclomethasone Dipropionate Metered Dose Inhaler (Inhalation Aerosol)(0.04 mg/INH): Subjects will receive one inhalation (0.04 mg/ INH) of Study medication twice daily
Control Intervent
Sponsors
Aurobindo Pharma Research CenterII
AXIS Clinicals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult male or female subjects of aged >=18 to 2. Diagnosis of asthma as defined by the National Asthma Education and Prevention Program at least 12 months prior to screening. 3. Pre-bronchodilator FEV1 of >= 45% and 4. >=15% and > 0.20 L reversibility of FEV1 within 30 minutes following 360 mcg of Salbutamol inhalation (pMDI) on the first day of treatment visit. 5. Subjects with FeNO > 25 ppb at screening and on the first day of treatment visit. 6. Subjects stable on their chronic asthma treatment regimen for at least four weeks prior to enrollment. 7. Subject should able to replace current SABAs with Salbutamol inhaler for use as needed for the duration of the study. 8. Subject should be able to withhold all inhaled SABAs for at least six hours prior to lung function assessments on study visits. 9. Ability to discontinue their asthma medications (inhaled corticosteroids and long-acting β agonists) during the run-in period and for remainder of the study. 10. Asthma patients who are stable on low dose ICS or low dose ICS+LABA or who will be stable with low dose ICS as per Investigatorâ??s clinical judgement. 11. Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and having had 12. Willingness to give their written informed consent to participate in the study. 13. Subjects willing to perform all study related procedures including the use of study inhalers, Spirometry and willing to complete the Subject diary. 14. Female of child-bearing potential, agreed to use a reliable method of contraception during study (e.g., condom + spermicide, IUD, oral, transdermal, injected or implanted hormonal contraceptives).
Exclusion criteria
Exclusion criteria: 1. Life-threatening asthma, a history of asthma episodes(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma related syncopal episode(s). 2. Hospitalizations within the past year prior to the screening for the conditions mentioned in exclusion criteria No.01 or during the run-in period. 3. Significant respiratory disease other than asthma (COPD, interstitial lung disease, etc.) 4. Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension 5. Evidence or history of clinically significant disease or abnormality including uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. 6. Historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that, in the opinion of the investigator, would put the subject at risk through study participation, or would affect the study analyses if the disease exacerbates during the study. 7. Viral or bacterial, upper or lower respiratory tract infection, or sinus, or middle ear infection within four weeks prior to the screening, during the run-in period, or on the day of treatment. 8. Hypersensitivity to Beclomethasone or any of the ingredients of the formulation and any sympathomimetic drug (e.g., Salbutamol) or any inhaled, intranasal, or systemic corticosteroid therapy. 9. Subjects receiving β2-blockers, anti-arrhythmics, anti-depressants, and monoamine oxidase inhibitors within 4 weeks prior to the screening. 10. Subjects who required systemic corticosteroids (for any reason) within the past 2 months. 11. Clinically significant abnormalities in ECG at screening as per investigators discretion. 12. Female subjects who are pregnant, nursing or planning a pregnancy during the study. 13. Subjects who have participated in another investigational drug or device research study within 30 days of screening. 14. Subjects who are using any medication or has any disease which in the judgment of the Investigator will interfere with the conduct or interpretation of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in Forced Expiratory volume in 1 second (FEV 1) from baseline (visit 3) to end of study visit (visit 5). Timepoint: Visit 1, 2, 3, 4 and 5 | — |
Secondary
| Measure | Time frame |
|---|---|
| â?¢ Mean change in FeNO value from base line (visit 1 & 3) to end of study visit (visit 5) â?¢ Percentage of subjects with reduction of FeNO from BaselineTimepoint: Visit 1,3,and 5 | — |
Countries
India
Contacts
Public ContactDr Subhra Lahiri
AXIS Clinicals Ltd
Outcome results
None listed